As filed with the Securities and Exchange Commission on September 11, 2023
Registration No. 333-273219
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 3
TO
Form S-1
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
INTELLIGENT BIO SOLUTIONS INC.
(Exact name of registrant as specified in its charter)
Delaware | 3829 | 82-1512711 | ||
(State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | ||
incorporation or organization) | Classification Code Number) | Identification Number) |
142 West 57th Street, 11th Floor
New York, New York 10019
Telephone: (646) 828-8258
(Address, including zip code, and telephone number, including area code, of
registrant’s principal executive offices)
Harry Simeonidis
Chief Executive Officer and President
142 West 57th Street, 11th Floor
New York, New York 10019
Telephone: (646) 828-8258
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copy to:
Ralph V. De Martino, Esq. Johnathan Duncan, Esq. ArentFox Schiff LLP 901 K Street NW, Suite 700, Washington, DC 20001 Telephone: (202) 724-6848 | Michael F. Nertney, Esq. Ellenoff Grossman & Schole LLP 1345 Avenue of the Americas New York, NY 10105-0302 (212) 370-1300 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after the registration statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:
Large accelerated filer ☐ | Accelerated filer ☐ | |
Non-accelerated filer ☒ | Smaller reporting company ☒ | |
Emerging growth company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY NOTE
Intelligent Bio Solutions, Inc. is filing this Amendment No. 3 (this “Amendment”) to its Registration Statement on Form S-1 (File No. 333-273219) (the “Registration Statement”) as an exhibits-only filing. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16(a) of Part II of the Registration Statement, the signature page to the Registration Statement and the filed exhibits. The remainder of the Registration Statement is unchanged and has been omitted.
Item 16. Exhibits and Financial Statement Schedules.
(a) Exhibits
*Indicates management contract or compensatory plan.
** Filed herewith
† Previously Filed
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Sydney, Australia, on September 11, 2023.
INTELLIGENT BIO SOLUTIONS INC. | ||
By: | /s/ Harry Simeonidis | |
Name: | Harry Simeonidis | |
Title: | Chief Executive Officer and President |
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Name | Position | Date | ||
/s/ Harry Simeonidis | President, Chief Executive Officer and Director | September 11, 2023 | ||
Harry Simeonidis | ||||
/s/ Spiro Sakiris | Chief Financial Officer | September 11, 2023 | ||
Spiro Sakiris | (Principal Financial Officer and Principal Accounting Officer) | |||
* | Chairman of the Board | September 11, 2023 | ||
Steven Boyages MB BS, PhD | ||||
* | Director | September 11, 2023 | ||
Lawrence Fisher | ||||
* | Director | September 11, 2023 | ||
Jonathan Hurd | ||||
* | Director | September 11, 2023 | ||
Jason Isenberg | ||||
* | Director | September 11, 2023 | ||
David Jenkins | ||||
* | Director | September 11, 2023 | ||
Christopher Towers |
*By: | /s/ Spiro Sakiris | |
Spiro Sakiris | ||
Attorney-in-fact |